The knowledge in the field of castration-resistant prostate cancer (CRPC) is developing rapidly, with emerging new therapies and advances in imaging. Nonetheless, in multiple areas there is still a lack of or very limited evidence, and clear guidance from clinicians regarding optimal strategy is required.
A modified Delphi method, with 116 relevant questions divided into 7 different CRPC management topics, was used to develop a consensus statement by the URONCOR group.
A strong consensus or unanimity was reached on 93% of the proposed questions. The seven topics addressed were: CRPC definition, symptomatic patients, diagnosis of metastasis, CRPC progression, M0 management, M1 management and sequencing therapy, and treatment monitoring.
The recommendations based on the radiation oncology experts' opinions are intended to provide cancer specialists with expert guidance and to standardise CRPC patient management in Spain, facilitating decision-making in different clinically relevant issues regarding CRPC patients.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2018 Oct 06 [Epub ahead of print]
A Gómez-Caamaño, C González-San Segundo, I Henríquez, X Maldonado, A Zapatero, Expert Panel for the Consensus on Management of Castration-Resistant Prostate Cancer 2017, Urological Tumours Working Group (URONCOR), Spanish Society of Radiation Oncology (SEOR)
Radiation Oncology Department, Hospital Clínico Universitario de Santiago de Compostela, A Coruña, Spain. ., Radiation Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Radiation Oncology Department, Hospital Universitario Sant Joan de Reus, Tarragona, Spain., Radiation Oncology Department, Hospital Campus Vall d'Hebron, Barcelona, Spain., Radiation Oncology Department, Hospital Universitario de La Princesa, Madrid, Spain.